CommercialCoverageMedium impact
Intermittent Intravenous Insulin Therapy (CPB 0742, reviewed 2026-10-16)
Aetna·Endocrinology, Internal Medicine·Medical Policy
We identified it
Oct 19, 2026
Summary
Aetna's Clinical Policy Bulletin 0742 (reviewed 2026-10-16) classifies intermittent intravenous insulin therapy and related diagnostic tests as experimental, investigational, or unproven. Specific CPT codes (82947, 82948, 82950, 84132, 84133, 84540) and HCPCS codes (G9147, J1811–J1815, J1817, S5550–S5571) are not covered when performed in the context of this therapy. The policy explicitly excludes insulin infusions for diabetic ketoacidosis and hyperosmolar coma from this non-coverage determination.
Action Required
Verify current applicability of this policy with Aetna: Billing and clinical staff should confirm whether this experimental/investigational determination has been superseded by more recent Aetna guidance, as the source document shows only a 2026-10-16 review date with no explicit effective date stated. If the policy remains active, implement the following: (1) Update billing system to flag claims for CPT codes 82947, 82948, 82950, 84132, 84133, 84540 and HCPCS code G9147 when submitted in the context of intermittent intravenous insulin therapy for non-coverage denial; (2) Ensure providers and billing staff understand that insulin codes J1811–J1815, J1817, S5550–S5571 are not covered for this indication; (3) Continue to allow coverage for insulin infusions used specifically for diabetic ketoacidosis or hyperosmolar coma, as these are explicitly excluded from the non-coverage restriction; (4) Request prior authorization or contact Aetna directly before submitting claims for these services to avoid denials and rework.